Caseware UK (AP4) 2024.0.164 2024.0.164 2025-09-30 2025-09-30 The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 2024-10-01 true false Medical 2 2 true 10394732 2024-10-01 2025-09-30 10394732 2023-10-01 2024-09-30 10394732 2025-09-30 10394732 2024-09-30 10394732 c:Director1 2024-10-01 2025-09-30 10394732 d:OfficeEquipment 2024-10-01 2025-09-30 10394732 d:OfficeEquipment 2025-09-30 10394732 d:OfficeEquipment 2024-09-30 10394732 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-10-01 2025-09-30 10394732 d:CurrentFinancialInstruments 2025-09-30 10394732 d:CurrentFinancialInstruments 2024-09-30 10394732 d:CurrentFinancialInstruments d:WithinOneYear 2025-09-30 10394732 d:CurrentFinancialInstruments d:WithinOneYear 2024-09-30 10394732 d:ShareCapital 2025-09-30 10394732 d:ShareCapital 2024-09-30 10394732 d:RetainedEarningsAccumulatedLosses 2025-09-30 10394732 d:RetainedEarningsAccumulatedLosses 2024-09-30 10394732 d:AcceleratedTaxDepreciationDeferredTax 2025-09-30 10394732 d:AcceleratedTaxDepreciationDeferredTax 2024-09-30 10394732 c:OrdinaryShareClass1 2024-10-01 2025-09-30 10394732 c:OrdinaryShareClass1 2025-09-30 10394732 c:OrdinaryShareClass1 2024-09-30 10394732 c:FRS102 2024-10-01 2025-09-30 10394732 c:AuditExempt-NoAccountantsReport 2024-10-01 2025-09-30 10394732 c:FullAccounts 2024-10-01 2025-09-30 10394732 c:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 10394732 2 2024-10-01 2025-09-30 10394732 e:PoundSterling 2024-10-01 2025-09-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 10394732 SOLANUM MEDICAL COMMUNICATIONS LIMITED UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 30 SEPTEMBER 2025
SOLANUM MEDICAL COMMUNICATIONS LIMITED REGISTERED NUMBER: 10394732 BALANCE SHEET AS AT 30 SEPTEMBER 2025
|  | 2025 |  | 2024
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Tangible assets | 4 |  | 751 |  | 457
|  |  | 751 |  | 457
Current assets |  |  |  |  |
Debtors: amounts falling due within one year | 5 | 25,308 |  | 16,185 |
Cash at bank and in hand |  | 112,829 |  | 116,876 |
|  | 138,137 |  | 133,061 |
Creditors: amounts falling due within one year | 6 | (31,554) |  | (32,840) |
Net current assets |  |  | 106,583 |  | 100,221
Total assets less current liabilities |  |  | 107,334 |  | 100,678
Provisions for liabilities |  |  |  |  |
Deferred tax | 7 | (188) |  | (114) |
|  |  | (188) |  | (114)
Net assets |  |  | 107,146 |  | 100,564
Capital and reserves |  |  |  |  |
Called up share capital |  |  | 3 |  | 3
Profit and loss account |  |  | 107,143 |  | 100,561
|  |  | 107,146 |  | 100,564
Page 1
SOLANUM MEDICAL COMMUNICATIONS LIMITED REGISTERED NUMBER: 10394732 BALANCE SHEET (CONTINUED) AS AT 30 SEPTEMBER 2025 The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
................................................ Mrs B Gonzalez
Director
Date: 9 March 2026
The notes on pages 3 to 8 form part of these financial statements. Page 2
SOLANUM MEDICAL COMMUNICATIONS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025
1. | General information
Solanum Medical Communications Limited is a private company, company number 10394732, limited by shares, incorporated in England and Wales, with its registered office and principal place of business at Llain y Saer, Capel Coch, Llangefni, LL77 7UT 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the requirements and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The following principal accounting policies have been applied:
| 2.2 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably.
| 2.3 | Interest income
Interest income is recognised in profit or loss using the effective interest method.
| 2.4 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument. Page 3
SOLANUM MEDICAL COMMUNICATIONS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025 2.Accounting policies (continued)
| 2.5 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.
| 2.6 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, see below for the appropriate depreciation methods. Depreciation is provided on the following basis:
|  |  |  | Office equipment | - | 33% | straight line
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
| 2.7 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.8 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.9 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Page 4
SOLANUM MEDICAL COMMUNICATIONS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025 2.Accounting policies (continued)
| 2.10 | Provisions for liabilities
Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made. Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties. Increases in provisions are generally charged as an expense to profit or loss.
| 2.11 | Dividends
Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.
3. | Employees
| The average monthly number of employees, including directors, during the year was 2 (2024 - 2).
Page 5
SOLANUM MEDICAL COMMUNICATIONS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025
4. | Tangible fixed assets
|  | Office equipment
|  | £
| Cost or valuation |
| At 1 October 2024 | 6,365
| Additions | 1,127
| Disposals | (165)
| At 30 September 2025 | 7,327
| Depreciation |
| At 1 October 2024 | 5,909
| Charge for the year on owned assets | 832
| Disposals | (165)
| At 30 September 2025 | 6,576
| Net book value |
| At 30 September 2025 | 751
| At 30 September 2024 | 457
5. | Debtors
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Trade debtors | 24,730 | 15,649
| Prepayments and accrued income | 578 | 536
|  | 25,308 | 16,185
Page 6
SOLANUM MEDICAL COMMUNICATIONS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025
6. | Creditors: Amounts falling due within one year
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Trade creditors | 200 | -
| Corporation tax | 16,689 | 22,045
| Other taxation and social security | 11,818 | 8,802
| Other creditors | 177 | 43
| Accruals and deferred income | 2,670 | 1,950
|  | 31,554 | 32,840
7. | Deferred taxation
|  | 2025
|  | £
| At beginning of year | (114)
| Utilised in year | (74)
| At end of year | (188)
| The provision for deferred taxation is made up as follows:
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Accelerated capital allowances | (188) | (114)
|  | (188) | (114)
8. | Share capital
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 3 (2024 - 3) Ordinary shares of £1.00 each | 3 | 3
Page 7
SOLANUM MEDICAL COMMUNICATIONS LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025
9. | Pension commitments
The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £60,000 (2024 - £70,000) No contributions were payable to the fund at the balance sheet date and included in creditors
Page 8